DAFTAR PUSTAKA

1. Joachim C, Macni J, Drame M, et al. Overall survival of colorectal cancer by stage at diagnosis: Data from the Martinique Cancer Registry. *Medicine (Baltimore)*. 2019;98(35):e16941. doi:10.1097/MD.0000000000016941

2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209-249. doi:10.3322/caac.21660

3. Pourhoseingholi MA. Increased burden of colorectal cancer in Asia. *World J Gastrointest Oncol*. 2012;4(4):68. doi:10.4251/wjgo.v4.i4.68

4. Yiu HY, Whittemore AS, Shibata A. Increasing colorectal cancer incidence rates in Japan. *Int J Cancer*. 2004;109(5):777-781. doi:10.1002/ijc.20030

5. Aune D, Chan DSM, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: Systematic review and dose-response meta-analysis of prospective studies. *BMJ (Clinical Res Ed)*. 2011;343:d6617-d6636.

6. Moore KJ, Sussman DA, Koru-Sengul T. Age-specific risk factors for advanced stage colorectal cancer, 1981-2013. *Prev Chronic Dis*. 2018;15(8):1-6. doi:10.5888/pcd15.170274

7. Yarbro JW, Page DL, Fielding LP, Partridge EE, Murphy GP. American Joint Committee on Cancer prognostic factors consensus conference. *Cancer*. 1999;86(11):2436-2446. doi:10.1002/(sici)1097-0142(19991201)86:11<2436::aid-cncr35>3.0.co;2-%23

8. Dolan RD, McSorley ST, Horgan PG, Laird B, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2017;116:134-146. doi:https://doi.org/10.1016/j.critrevonc.2017.06.002

9. Sideras K, Kwekkeboom J. Cancer inflammation and inflammatory biomarkers: can neutrophil, lymphocyte, and platelet counts represent the complexity of the immune system? *Transpl Int*. 2014;27(1):28-31.

42

doi:https://doi.org/10.1111/tri.12229

10. Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. *J Cancer Res Clin Oncol*. 2014;140(9):1537-1549. doi:10.1007/s00432-014-1714-3

11. Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis. *Int J Cancer*. 2014;134(10):2403-2413. doi:10.1002/ijc.28536

12. Stojkovic Lalosevic M, Pavlovic Markovic A, Stankovic S, et al. Combined Diagnostic Efficacy of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Mean Platelet Volume (MPV) as Biomarkers of Systemic Inflammation in the Diagnosis of Colorectal Cancer. *Dis Markers*. 2019;2019:6036979. doi:10.1155/2019/6036979

13. Beal EW, Cloyd JM. Neutrophil-to-Lymphocyte Ratio in Colorectal Liver Metastases: Simply Prognostic or Clinically Relevant? *Ann Surg Oncol*. 2021;28(8):4072-4073. doi:10.1245/s10434-021-10054-6

14. Hayama T, Hashiguchi Y, Okada Y, et al. Significance of the 7th postoperative day neutrophil-to-lymphocyte ratio in colorectal cancer. *Int J Colorectal Dis*. 2019;35:119-124.

15. Lu C, Gao P, Yang Y, et al. Prognostic evaluation of platelet to lymphocyte ratio in patients with colorectal cancer. *Oncotarget*. 2017;8(49):86287-86295. doi:10.18632/oncotarget.21141

16. Ozdemir Y, Akin ML, Sucullu I, Balta AZ, Yuce E. Pretreatment neutrophil/lymphocyte ratio as a prognostic aid in colorectal cancer. *Asian Pacific J Cancer Prev*. 2014;15(6):2647-2650. doi:10.7314/APJCP.2014.15.6.2647

17. Kurt M, Onal IK, Sayılır A, et al. The role of mean platelet volume in the diagnosis of hepatocellular carcinoma in patients with chronic liver disease. *Hepatogastroenterology*. 2012;59 117:1580-1582.

18. Azab B, Shah N, Akerman M, McGinn JT. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial

infarction. *J Thromb Thrombolysis*. 2012;34(3):326—334. doi:10.1007/s11239-012-0718-6

19.   Gvirtzman R, Livovsky DM, Tahover E, Goldin E, Koslowsky B. Anemia can predict the prognosis of colorectal cancer in the pre-operative stage: a retrospective analysis. *World J Surg Oncol*. 2021;19(1):341. doi:10.1186/s12957-021-02452-7

20.   Turhan VB, Ünsal A, Gök HF, et al. Predictive Value of Preoperative Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratio in Determining the Stage of Colon Tumors. *Cureus*. 2021;13(9). doi:10.7759/cureus.18381

21.   Song Y, Yang Y, Gao P, et al. The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer. *BMC Cancer*. 2017;17(1):1-8. doi:10.1186/s12885-017-3752-0

22.   A. RK, A. V. AK. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratios correlate with staging in patients with colorectal carcinoma. *Int Surg J*. 2020;7(12):4094. doi:10.18203/2349-2902.isj20204991

23.   Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-E386. doi:10.1002/ijc.29210

24.   O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. *Am Surg*. 2003;69(10):866—872. http://europepmc.org/abstract/MED/14570365

25.   Frans\'e;n K, Klintenäs M, Österström A, Dimberg J, Monstein HJ, Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. *Carcinogenesis*. 2004;25(4):527-533. doi:10.1093/carcin/bgh049

26.   Arnold CN, Goel A, Blum HE, Richard Boland C. Molecular pathogenesis of colorectal cancer. *Cancer*. 2005;104(10):2035-2047. doi:https://doi.org/10.1002/cncr.21462

27.   Deng Y, Peng J, Zhao Y, et al. Lymph node ratio as a valuable prognostic factor for patients with colorectal liver-only metastasis undergoing curative

resection. *Cancer Manag Res*. 2018;10:2083-2094. doi:10.2147/CMAR.S169029

28.　Sharkas GF, Arqoub KH, Khader YS, et al. Colorectal Cancer in Jordan: Survival Rate and Its Related Factors. *J Oncol*. 2017;2017. doi:10.1155/2017/3180762

29.　Robertson DJ, Dominitz JA. Stool DNA and Colorectal-Cancer Screening. *N Engl J Med*. 2014;370(14):1350-1351. doi:10.1056/NEJMe1400092

30.　Zerhouni E. Bethesda criteria. *J Natl Cancer Inst*. 2004;96(4):261-268. http://www.sciencemag.org/content/306/5703/1895.short

31.　Thirunavukarasu P, Sukumar S, Sathaiah M, et al. C-stage in Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker in Staging, Prognosis, and Management. *JNCI J Natl Cancer Inst*. 2011;103(8):689-697. doi:10.1093/jnci/djr078

32.　Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. *J Clin Oncol*. 2017;35(13):1453-1486. doi:10.1200/JCO.2016.71.9807

33.　Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. *CA Cancer J Clin*. 2017;67(2):93-99. doi:https://doi.org/10.3322/caac.21388

34.　Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: Pathologic aspects. *J Gastrointest Oncol Vol 3, No 3 (September 01, 2012) J Gastrointest Oncol (Current Top Gastrointest Liver Pathol*. Published online 2012. https://jgo.amegroups.org/article/view/410

35.　Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. *Histopathology*. 2020;76(2):182-188. doi:10.1111/his.13975

36.　Kumar A, Kennecke HF, Renouf DJ, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.

Cancer. 2015;121(4):527-534. doi:https://doi.org/10.1002/cncr.29072

37. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell*. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013

38. Ikeda M, Furukawa H, Imamura H, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. *Ann Surg Oncol*. 2002;9(3):287-291. doi:10.1007/BF02573067

39. Victorino V, Jeremias I, Assunção A. Immunological Processes in Cancer: A Link Between Inflammation and Immunity. *Am J Immunol*. 2014;10:189-201. doi:10.3844/ajisp.2014.189.201

40. Maiorino L, Egeblad M. Tumours pick the path to cancer inflammation. *Nat Cell Biol*. 2019;21(9):1055-1057. doi:10.1038/s41556-019-0386-2

41. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature*. 2008;454(7203):436-444. doi:10.1038/nature07205

42. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. *Nature*. 2003;425(6957):516-521. doi:10.1038/nature01991

43. McDonald B, Spicer JD, Giannais B, Fallavollita L, Brodt P, Ferri LE. Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. *Int J Cancer*. 2009;125. https://api.semanticscholar.org/CorpusID:19389775

44. Mariani F, Sena P, Roncucci L. Inflammatory pathways in the early steps of colorectal cancer development. *World J Gastroenterol*. 2014;20(29):9716—9731. doi:10.3748/wjg.v20.i29.9716

45. Tecchio C, Cassatella MA. Neutrophil-Derived Cytokines Involved in Physiological and Pathological Angiogenesis. Granata F, Marone G, eds. *Angiogenesis, Lymphangiogenes Clin Implic*. 2013;99:0. doi:10.1159/000353358

46. Selders GS, Fetz AE, Radic MZ, Bowlin GL. An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration. *Regen Biomater*. 2017;4(1):55-68. doi:10.1093/rb/rbw041

47. Wang Z, Jin H, Xu R, Mei Q, Fan D. Triptolide downregulates Rac1 and

the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. *Exp Mol Med*. 2009;41:717-727. doi:10.3858/emm.2009.41.10.078

48. Uribe-Querol E, Rosales C. Neutrophils in cancer: Two sides of the same coin. *J Immunol Res*. 2015;2015. doi:10.1155/2015/983698

49. Jeske WP. 10 - Platelet production, structure, and function. In: Keohane EM, Otto CN, Walenga JM, eds. *Rodak's Hematology (Sixth Edition)*. Sixth Edit. Elsevier; 2020:136-153. doi:https://doi.org/10.1016/B978-0-323-53045-3.00019-2

50. Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. *Cancer Res*. 1999;59 6:1295-1300. https://api.semanticscholar.org/CorpusID:14537110

51. Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelets Effects on Tumor Growth. *Semin Oncol*. 2014;41(3):359-369. doi:https://doi.org/10.1053/j.seminoncol.2014.04.006

52. Tang H, Li B, Zhang A, Lu W, Xiang C, Dong J. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Colorectal Liver Metastasis: A Systematic Review and Meta-Analysis. *PLoS One*. 2016;11(7):1-15. doi:10.1371/journal.pone.0159447

53. Au AEL, Sashindranath M, Borg RJ, et al. Activated platelets rescue apoptotic cells via paracrine activation of EGFR and DNA-dependent protein kinase. *Cell Death Dis*. 2014;5(9):1-13. doi:10.1038/cddis.2014.373

54. BAMBACE NM, HOLMES CE. The platelet contribution to cancer progression. *J Thromb Haemost*. 2011;9(2):237-249. doi:10.1111/j.1538-7836.2010.04131.x

55. Schlesinger M. Role of platelets and platelet receptors in cancer metastasis 06 Biological Sciences 0601 Biochemistry and Cell Biology. *J Hematol Oncol*. 2018;11(1):1-15. doi:10.1186/s13045-018-0669-2

56. Omman RA, Kini AR. 9 - Leukocyte development, kinetics, and functions. In: Keohane EM, Otto CN, Walenga JM, eds. *Rodak's Hematology (Sixth Edition)*. Sixth Edit. Elsevier; 2020:117-135.

doi:https://doi.org/10.1016/B978-0-323-53045-3.00018-0

57. Spicer JD, McDonald B, Cools-Lartigue JJ, et al. Neutrophils Promote Liver Metastasis via Mac-1–Mediated Interactions with Circulating Tumor Cells. *Cancer Res*. 2012;72(16):3919-3927. doi:10.1158/0008-5472.CAN-11-2393

58. Tan D, Fu Y, Tong W, Li F. Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: A meta-analysis. *Int J Surg*. 2018;55:128-138. doi:https://doi.org/10.1016/j.ijsu.2018.05.030

59. Pine JK, Morris E, Hutchins GG, et al. Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: The relationship to patient survival, tumour biology and local lymphocytic response to tumour. *Br J Cancer*. 2015;113(2):204-211. doi:10.1038/bjc.2015.87

60. Ho CH, Yu Y Bin, Wu PH. The prevalence of iron deficiency anemia and its clinical implications in patients with colorectal carcinoma. *J Chinese Med Assoc*. 2008;71(3):119-122. doi:10.1016/S1726-4901(08)70002-9

61. Who, Chan M. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. *Geneva, Switz World Heal Organ*. Published online 2011:1-6. doi:2011

62. Edna TH, Karlsen V, Jullumstrø E, Lydersen S. Prevalence of anaemia at diagnosis of colorectal cancer: Assessment of associated risk factors. *Hepatogastroenterology*. 2012;59(115):713-716. doi:10.5754/hge11479

63. Al-Saeed EF, Tunio MA, Al-Obaid O, et al. Correlation of pretreatment hemoglobin and platelet counts with clinicopathological features in colorectal cancer in Saudi population. *Saudi J Gastroenterol*. 2014;20(2):134-138. doi:10.4103/1319-3767.129479

64. Väyrynen JP, Tuomisto A, Väyrynen SA, et al. Preoperative anemia in colorectal cancer: Relationships with tumor characteristics, systemic inflammation, and survival. *Sci Rep*. 2018;8(1):1-11. doi:10.1038/s41598-018-19572-y

65. Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? *BMC Res Notes*.

2017;10(1):1-4. doi:10.1186/s13104-016-2335-5

66. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. *Br J Cancer*. 2011;104(8):1288-1295. doi:10.1038/bjc.2011.100

67. Ferradini L, Miescher S, Stoeck M, et al. Cytotoxic potential despite impaired activation pathways in T lymphocytes infiltrating nasopharyngeal carcinoma. *Int J Cancer*. 1991;47(3):362-370. doi:https://doi.org/10.1002/ijc.2910470309

68. Shen L, Zhang H, Liang L, et al. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. *Radiat Oncol*. 2014;9(1):295. doi:10.1186/s13014-014-0295-2

69. Kaneko M, Nozawa H, Sasaki K, et al. Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy. *Oncology*. 2012;82:261-268. https://api.semanticscholar.org/CorpusID:22830261

70. An X, Mao HP, Wei X, et al. Elevated neutrophil to lymphocyte ratio predicts overall and cardiovascular mortality in maintenance peritoneal dialysis patients. *Int Urol Nephrol*. 2012;44(5):1521-1528. doi:10.1007/s11255-012-0130-3

71. Shiny A, Bibin YS, Shanthirani CS, et al. Association of Neutrophil-Lymphocyte Ratio with Glucose Intolerance: An Indicator of Systemic Inflammation in Patients with Type 2 Diabetes. *Diabetes Technol Ther*. 2014;16(8):524-530. doi:10.1089/dia.2013.0264

72. Li Z, Xu Z, Huang Y, et al. Prognostic values of preoperative platelet-tolymphocyte ratio, albumin and hemoglobin in patients with non-metastatic colon cancer. *Cancer Manag Res*. 2019;11:3265-3274. doi:10.2147/CMAR.S191432

73. Fernandes JV, Cobucci RNO, Jatobá CAN, de Medeiros Fernandes TAA, de Azevedo JWV, de Araújo JMG. The Role of the Mediators of Inflammation in Cancer Development. *Pathol Oncol Res*. 2015;21(3):527-

534. doi:10.1007/s12253-015-9913-z

74. Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE. Platelets in Tumor Progression: A Host Factor That Offers Multiple Potential Targets in the Treatment of Cancer. *J Cell Physiol*. 2014;229(8):1005-1015. doi:https://doi.org/10.1002/jcp.24539

75. Kang Y, Zhu X, Lin Z, et al. Compare the Diagnostic and Prognostic Value of MLR, NLR and PLR in CRC Patients. *Clin Lab*. 2021;67(9). doi:10.7754/clin.lab.2021.201130

76. Jia W, Yuan L, Ni H, Xu B, Zhao P. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy. *Technol Cancer Res Treat*. 2021;20:1-10. doi:10.1177/15330338211034291

77. Chen N, Li W, Huang K, et al. Increased platelet-lymphocyte ratio closely relates to inferior clinical features and worse long-term survival in both resected and metastatic colorectal cancer: An updated systematic review and meta-analysis of 24 studies. *Oncotarget*. 2017;8(19):32356-32369. doi:10.18632/oncotarget.16020

78. Acikgoz O, Cakan B, Demir T, et al. Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer. *Med (United States)*. 2021;100(44):1-7. doi:10.1097/MD.0000000000027712

79. Dupont WD, Plummer WD. Power and Sample Size Calculations for Studies Involving Linear Regression. *Control Clin Trials*. 1998;19(6):589-601. doi:https://doi.org/10.1016/S0197-2456(98)00037-3

80. Li K, Yan J, Zhang H. Correlation between peripheral blood hemoglobin/erythrocyte distribution width ratio and prognosis of patients with primary colorectal cancer. *Medicine (Baltimore)*. 2023;102(23). https://journals.lww.com/md-journal/Fulltext/2023/06090/Correlation_between_peripheral_blood.12.aspx

81. Sadahiro S, Suzuki T, Tokunaga N, et al. Anemia in patients with colorectal cancer. *J Gastroenterol*. 1998;33(4):488-494. doi:10.1007/s005350050120